Introduction
============

Head and neck cancer (HNC) is the sixth most common cancer worldwide ([@b1-ol-0-0-10616]). Annually, about 650,000 new cases and 350,000 deaths are reported worldwide, accounting for 6% of all cases ([@b1-ol-0-0-10616],[@b2-ol-0-0-10616]). High-risk regions for lip and oral cavity cancers include Melanesia, South-Central Asia, and Central and Eastern Europe ([@b2-ol-0-0-10616]). High-risk regions for laryngeal cancer include Southern and Eastern Europe and Western Asia ([@b2-ol-0-0-10616]). Indonesia, Singapore, and Malaysia, which are inhabited to a large extent by Malay and Chinese individuals, have the highest incidence of nasopharyngeal carcinoma ([@b3-ol-0-0-10616]). Mounting evidence suggests that genetic variations or abnormal expression of keratinocyte differentiation associated protein, heme oxygenase 1 (HMOX1), Rac family small GTPase 1 (Rac1), and desmocollin 1 (DSC1) may be associated with the carcinogenesis and progression of head and neck tumors. Studies have also found that HMOX1 and keratin-associated proteins are associated with human papillomavirus (HPV)-related HNC ([@b4-ol-0-0-10616],[@b5-ol-0-0-10616]). Inhibition of Rac1 activity may help to overcome primary or secondary chemo-radio-resistance in HNC ([@b6-ol-0-0-10616]). Occurrence and clinical prognosis of HNC are associated with overexpression of DSC1 ([@b7-ol-0-0-10616]). Early diagnosis and early treatment are keys to successful treatment of HNC, but no tumor markers with high specificity and sensitivity, or an effective therapeutic target, have been identified. Therefore, the survival rate and quality of life of patients with HNC is poor. As such, it is necessary to characterize the molecular mechanisms involved in the carcinogenesis of head and neck tumors. Better understanding of these mechanisms will allow for improved guidelines for diagnosis and treatment of head and neck tumors.

To explore the genetic alterations in head and neck tumors, identify new high-specificity and high-sensitivity tumor markers, and identify potentially effective therapeutic targets, *in silico* methods were used to study HNC. In the present study, GSE58911 was downloaded and analyzed from the Gene Expression Omnibus (GEO) database to obtain differentially expressed genes (DEGs) between HNC tissues and non-cancerous tissues. Subsequently, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, Gene Ontology (GO) enrichment analysis, and protein-protein interaction (PPI) network analysis was performed to characterize the molecular mechanisms underlying carcinogenesis and progression of HNC. A total of 648 differentially expressed genes and 26 hub genes were identified, which may be potential targets for clinical diagnosis and therapy of HNC.

Materials and methods
=====================

### Microarray data

Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo>) is a public functional genomics data repository of high throughout gene expression data, chips, and microarrays ([@b8-ol-0-0-10616],[@b9-ol-0-0-10616]). Platform (GPL) and Series (GSE) constitute the data from GEO. The gene expression dataset (GSE58911) ([@b10-ol-0-0-10616]) was downloaded from GEO (Affymetrix GPL6244, Affymetrix Human Gene 1.0 ST Array) and contains 15 HNC samples and 15 normal tissues distant to the HNC sample.

### Identification of DEGs

*DEGs* between cancerous and non-cancerous tissues were screened using GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r>). To identify genes that are differentially expressed across experimental conditions, GEO2R, an interactive web tool, allows users to compare \>2 groups of samples in a GEO Series. Results are presented as a table of genes ordered by significance. Log fold-change (FC) ≥1 or ≤-1 and adjusted P-value \<0.05 were considered to be statistically different.

### KEGG and GO enrichment analysis of DEGs

A comprehensive set of functional annotation tools were provided by the Database for Annotation, Visualization, and Integrated Discovery (DAVID; <http://david.ncifcrf.gov>) (version 6.8). DAVID is an online biological information database for investigators to understand biological significance underlying a large number of genes ([@b11-ol-0-0-10616]). KEGG (<http://www.kegg.jp>), an integrated database resource, is used for the biological interpretation of genome sequences and other high-throughput data ([@b12-ol-0-0-10616]). The GO ([www.geneontology.org](www.geneontology.org)) project is a major bioinformatics tool and represents the most comprehensive resource currently available for computable knowledge regarding the functions of genes and gene products ([@b13-ol-0-0-10616]). Enrichment analysis from GO and KEGG pathways for differentially expressed genes was obtained using DAVID. P\<0.05 was considered to indicate a statistically significant difference.

### PPI network construction and analysis

A PPI network of DEGs was constructed using the Search Tool for the Retrieval of Interacting Genes (STRING) online database (version 10.5; <http://string-db.org>) ([@b14-ol-0-0-10616]). Through the STRING database, DEGs with a combined score ≥0.4 were chosen to construct a PPI network which could be visualized using Cytoscape software (version 3.4.0; [www.cytoscape.org](www.cytoscape.org)) ([@b15-ol-0-0-10616]). The functional modules of the PPI network were then identified using the Molecular Complex Detection (MCODE) (version 1.4.2) plug-in of Cytoscape ([@b16-ol-0-0-10616]). The criteria for selection were as follows: Max depth, 100; degree cut-off, 2; k-score, 2 and node score cut-off, 0.2.

### Hub gene selection and analysis

Hub genes were selected using Cytoscape software. A network of hub genes and their co-expressed genes was analyzed using the cBioPortal for Cancer Genomics (<http://www.cbioportal.org>) ([@b17-ol-0-0-10616],[@b18-ol-0-0-10616]), which allows for visualization, analysis, and download of large-scale cancer genomics data sets. Hierarchical clusters of hub genes were constructed using the next generation University of California Santa Cruz (UCSC) Cancer Browser: UCSC Xena (<http://xena.ucsc.edu>) ([@b19-ol-0-0-10616]). The sample source 'The Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma (HNSC)' was selected for these 26 hub genetic analyses and 604 samples were selected for analysis. The overall survival and disease-free survival rate analyses of hub genes was performed by constructing Kaplan-Meier curves using the cBioPortal online platform (statistical analysis performed is a log-rank test). Furthermore, the relationship between expression patterns, tumor grades, and HPV infection status was analyzed using Oncomine (<https://www.oncomine.org>) ([@b20-ol-0-0-10616]--[@b29-ol-0-0-10616]).

Results
=======

### Identification and PPI network construction of DEGs in HNC

After the standardization of the microarray results, 648 differentially expressed genes were identified between HNC tissues and normal tissues. The results from the GSE58911 dataset are represented as a volcano plot ([Fig. 1A](#f1-ol-0-0-10616){ref-type="fig"}). The PPI network of DEGs was constructed ([Fig. 1B](#f1-ol-0-0-10616){ref-type="fig"}). There were 554 nodes and 1574 edges in the PPI network, and the average node score was 5.68 ([Fig. 1B](#f1-ol-0-0-10616){ref-type="fig"}).

### GO and KEGG pathway enrichment analyses of DEGs

To analyze the biological classification of DEGs, GO and KEGG pathway enrichment analyses were performed using DAVID ([Table I](#tI-ol-0-0-10616){ref-type="table"}). The results of GO analysis showed that changes in biological processes of DEGs were mainly 'enriched in muscle system process', 'extracellular matrix organization', 'muscle contraction', 'extracellular structure organization', and 'muscle filament sliding'. Molecular function DEGs included 'actin binding', 'structural constituent of muscle', 'cytoskeletal protein binding', 'structural molecule activity' and 'actinin binding'. Cell component DEGs included 'extracellular region part', 'contractile fiber', 'extracellular region', 'sarcomere', and 'myofibril'. KEGG pathway analysis showed that the DEGs were mainly enriched in 'extracellular matrix (ECM)-receptor interaction', 'focal adhesion', 'amoebiasis', 'drug metabolism-cytochrome P450', 'chemical carcinogenesis', 'dilated cardiomyopathy', 'small cell lung cancer', 'hypertrophic cardiomyopathy', and 'retinol metabolism'.

### Hub gene selection and analysis

Using the MCODE plug-in of Cytoscape, 26 genes were identified as hub genes. The results of GO and KEGG pathway analyses indicated that the hub genes were mainly enriched in 'extracellular matrix organization', 'collagen catabolic process', 'extracellular structure organization', 'multicellular organism catabolic process', 'collagen metabolic process', 'serine-type endopeptidase activity', 'extracellular matrix', 'proteinaceous extracellular matrix', 'extracellular space', 'extracellular region part', 'extracellular region', and 'complement and coagulation cascades' ([Table II](#tII-ol-0-0-10616){ref-type="table"}). The abbreviations, official full names, and synonyms for these hub genes are shown in [Table III](#tIII-ol-0-0-10616){ref-type="table"}. A network of the hub genes and their co-expressed genes was analyzed using cBioPortal for Cancer Genomics ([Fig. 2A](#f2-ol-0-0-10616){ref-type="fig"}). Hierarchical clustering revealed that the expression of hub genes could differentiate the HNC samples from normal samples ([Fig. 2B](#f2-ol-0-0-10616){ref-type="fig"}). From [figure 2B](#f2-ol-0-0-10616){ref-type="fig"}, it can be seen that 22 of the 26 hub genes were highly expressed in head and neck tumors compared with normal tissues, whereas expression of four genes (MMRN1/ECM1/EXCL12/CFD) was relatively high in the normal tissues. Furthermore, hierarchical clustering showed that HPV infection status determined by fluorescent *in situ* hybridization (FISH) testing ([Fig. 2C](#f2-ol-0-0-10616){ref-type="fig"}) and P16 testing ([Fig. 2D](#f2-ol-0-0-10616){ref-type="fig"}) was negatively associated with expression of the gene, although the mechanisms remains unknown. Overall survival rate analysis of the hub genes was performed using Kaplan-Meier curves in the cBioPortal online platform. Patients with HNC and high expression of interleukin (IL)8, IL1B and serpin family A member 1 (SERPINA1) had worse overall survival and worse disease-free survival ([Fig. 3A and B](#f3-ol-0-0-10616){ref-type="fig"}). Oncomine analysis of cancer vs. normal tissues indicated that IL8, IL1B, and SERPINA1 were over-expressed in HNC in the different datasets ([Fig. 4A, B and C](#f4-ol-0-0-10616){ref-type="fig"}). Higher mRNA expression levels of IL8 was associated with tumor grade (P=0.001). However, the mRNA expression levels of IL1B and SERPINA1 were not associated with tumor grade (P\>0.05). Higher mRNA expression levels of IL8 (P=6.30×10^−9^) and IL1B (P=3.48×10^−6^) were associated with HPV infection status. The mRNA expression levels of SERPINA1 however, were not associated with HPV infection status ([Fig. 5A-F](#f5-ol-0-0-10616){ref-type="fig"}).

Discussion
==========

HNC is the sixth most common cancer worldwide and is associated with severe disease- and treatment-related morbidity, with a 5-year survival rate of \<60% ([@b1-ol-0-0-10616],[@b2-ol-0-0-10616]). The survival rate has not improved across more than two decades due to lack of early detection ([@b30-ol-0-0-10616],[@b31-ol-0-0-10616]). There are two primary causes of HNC: Tobacco and alcohol use, and human papillomavirus infection ([@b32-ol-0-0-10616]). Previous studies have shown that HPV infection plays a role in the pathogenesis of head and neck tumors ([@b33-ol-0-0-10616]--[@b35-ol-0-0-10616]). The oncomine analysis of cancer vs. normal tissue for IL8, IL1B and SERPINA1 demonstrated that the expression was compared with the normal tissues ([Fig. 4](#f4-ol-0-0-10616){ref-type="fig"}). mRNA expressions of IL8, IL1B and SERPINA1 were higher in the HPV-negative group compared with that in the HPV-positive group ([Fig. 5D-F](#f5-ol-0-0-10616){ref-type="fig"}). These seemingly contradictory results are understandable. There are many studies suggesting that HPV-positive head and neck tumors were associated with improved disease-free and overall survival ([@b32-ol-0-0-10616],[@b36-ol-0-0-10616]). According to the present study, IL8, IL1B and SERPINA1 are highly expressed in the HNC, and the results in [Fig. 3](#f3-ol-0-0-10616){ref-type="fig"} indicate that the overall survival rate and disease-free survival rate of patients with high expression of these 3 genes are worse. Therefore, it is understandable that IL8, IL1B and SERPINA1 have higher expressions in HPV-negative tumor patients. However, the underlying molecular mechanisms of HNC remain unclear. Abnormal expression of transglutaminase 3, regenerating islet-derived protein 3, keratin 8, and phosphatase and tensin homolog is associated with HNC ([@b37-ol-0-0-10616]--[@b40-ol-0-0-10616]). In addition, mutations within tumor protein p53, notch receptor 1, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α, X-ray repair cross complementing 1 and epidermal growth factor receptor have been reported to be involved in HNC ([@b41-ol-0-0-10616]--[@b44-ol-0-0-10616]). Patients with HNC that do not detect the cancer early have no effective treatments available except receiving palliative care, which leads to poor prognosis and quality of life, and a high rate of mortality ([@b30-ol-0-0-10616]). Therefore, there is an urgent need to identify potential target biomarkers that can be used to efficiently diagnose and treat HNC. Bioinformatics technology allows us to explore genetic differences between HNC and normal tissues, which can be used to identify potential biomarkers. Then, effective genes can be selected through screening and experimental validation for early diagnosis, clinical prognosis, and treatment of HNC.

In the present study, the dataset GSE58911 was analyzed to obtain differentially expressed genes between HNC and non-cancerous tissues. A total of 648 DEGs were identified. GO and KEGG enrichment analyses were performed to explore interactions among these genes and they were mainly enriched in 'extracellular matrix organization', 'actin binding', 'extracellular region', 'ECM-receptor interaction', 'drug metabolism-cytochrome P450', and 'chemical carcinogenesis'. Previous studies reported that 'extracellular matrix organization', 'actin binding', and 'ECM-receptor interaction' play important roles in the carcinogenesis, progression, and metastasis of tumors ([@b45-ol-0-0-10616]--[@b48-ol-0-0-10616]). In addition, previous data indicated that focal adhesion, drug metabolism-cytochrome P450, and chemical carcinogenesis are involved in radio- and chemotherapy ([@b49-ol-0-0-10616]--[@b52-ol-0-0-10616]). Thus, the findings from the present study are consistent with results from previous studies. GO enrichment analysis indicated that changes in hub genes were mainly enriched in 'extracellular matrix organization', 'collagen catabolic process', 'serine-type endopeptidase activity', 'extracellular matrix', and 'proteinaceous extracellular matrix', while changes according to KEGG pathway analysis were mainly enriched in 'complement and coagulation cascades'.

A total of 26 DEGs were selected as hub genes, among which survival rates and disease-free survival rates between patients with head and neck tumors and patients without tumors were significantly associated with the expression of IL8, IL1B, and SERPINA1. IL8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes ([@b53-ol-0-0-10616]) and can be released by several cell types in response to inflammatory stimuli ([@b53-ol-0-0-10616]). Higher IL8 expression was observed in HNSCC tissue ([@b54-ol-0-0-10616],[@b55-ol-0-0-10616]). Furthermore, IL8 stimulated the proliferation of HNSC cells ([@b55-ol-0-0-10616],[@b56-ol-0-0-10616]). In addition, a previous study showed that the tumor microenvironment plays a vital role in HNC initiation, progression, and metastasis ([@b57-ol-0-0-10616]). Tumor-associated macrophages can promote cancer initiation and progression by releasing cytokines and may facilitate papillary thyroid carcinoma (PTC) cell metastasis through IL8 and its paracrine interaction with C-X-C chemokine receptor CXCR1 and CXCR2 ([@b58-ol-0-0-10616]). Thus, IL8 may be a potential therapeutic target.

IL1B is a potent pro-inflammatory cytokine. Initially discovered as the major endogenous pyrogen, IL1B induces prostaglandin synthesis, neutrophil influx and activation, cytokine production, T cell and B cell activation, antibody production, collagen production, and fibroblast proliferation ([@b59-ol-0-0-10616]). A recent study of IL1B has shown that it plays a major role in tumor chemotherapy resistance. Anakinra can block the IL-1 pathway and overcome erlotinib resistance in HNSCC, which may represent a novel strategy to overcome EGFR inhibitor resistance, allowing for more effective treatment of patients with HNSCC ([@b60-ol-0-0-10616]). Furthermore, high expression of inflammatory cytokines (IL8, IL1B) and shorter progression-free survival are significantly associated. The expression level of inflammatory cytokines may help to identify which patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck are likely to benefit from dacomitinib ([@b61-ol-0-0-10616]).

SERPINA1, an inhibitor of serine proteases, irreversibly inhibits trypsin, chymotrypsin, and plasminogen activator ([@b62-ol-0-0-10616]). Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin ([@b62-ol-0-0-10616]). A recent study showed a higher abundance of SERPINA1 candidate biomarkers in the saliva of patients with oral squamous cell carcinoma (OSCC), demonstrating that SERPINA1 is related to OSCC development ([@b63-ol-0-0-10616]). Moreover, SERPINA1 may be related to PTC by responding to steroid hormone stimuli and regulating the epithelial-to-mesenchymal transition ([@b64-ol-0-0-10616]). Based on these associations, SERPINA1 may be an effective mRNA marker of PTC ([@b65-ol-0-0-10616]). Oncomine analysis indicated that higher mRNA levels of IL8, IL1B, and SERPINA1 were associated with tumor grade and HPV infection status, indicating vital roles of IL8, IL1B, and SERPINA1 in the carcinogenesis or progression of HNC.

In addition to IL1B, lL8 and SERPINA1, which were associated with the survival rate of patients with head and neck cancer, other relevant hub genes that were identified in the present study are discussed.

Tenascin C (TNC), a gene associated with tumor metastatic potential, was upregulated in the OSCC cell line LNMTca8113 ([@b66-ol-0-0-10616]). In addition, vascular density and higher tumor stage were associated with differences in immuno-expression of stromal TNC, demonstrating its role in the tumorigenesis of juvenile nasopharyngeal angiofibroma ([@b67-ol-0-0-10616]).

A previous study showed that microRNA-29a/b could regulate the expression of collagen type III alpha 1 chain to enhance migration and invasion ability of nasopharyngeal carcinoma cells ([@b68-ol-0-0-10616]). The markers, the combination of collagen type V alpha 1 chain (COL5A1) and hemoglobin subunit beta and COL5A1 itself can better predict the treatment response in patients with oral tongue squamous cell carcinoma ([@b69-ol-0-0-10616]).

Poor disease-free survival and increased progression or relapse risk were associated with high plasminogen activator, urokinase (PLAU) expression. Moreover, circulating PLAU levels were significantly higher in the plasma of patients with HNSCC compared with that in healthy individuals ([@b70-ol-0-0-10616]).

Extracellular matrix protein 1 (ECM1) levels gradually increased from benign laryngeal lesions to precancerous to malignant lesions, and ECM1 was expressed at lower levels in laryngeal carcinomas without metastasis ([@b71-ol-0-0-10616],[@b72-ol-0-0-10616]). These results demonstrated that ECM1 facilitated development and metastasis of laryngeal carcinoma.

Overexpression of SERPINE1 promotes tumor migration and invasion and plays an important role in metastasis and poor prognosis of HNSCC ([@b73-ol-0-0-10616]). In addition, many researchers regard SERPINE1 as a prognostic marker based on its ability to stratify patients with HNSCC according to their recurrence risk ([@b74-ol-0-0-10616]).

Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that promote invasion and metastasis of various cancers due to their ability to degrade components of the extracellular matrix. MMP1, MMP3, MMP9, and MMP13 are predictors of poor clinical outcomes in patients with HNC ([@b75-ol-0-0-10616]--[@b78-ol-0-0-10616]). Furthermore, specific tissue inhibitors of matrix metalloproteinases (TIMPs) can regulate MMP activity. In addition to HNC, the majority of tumors are associated with alterations in MMPs and TIMPs. Imbalance between matrix metalloproteinases and their inhibitors contributes greatly to the progression and prognosis of HNC ([@b76-ol-0-0-10616],[@b79-ol-0-0-10616]).

Compared with normal oral mucosa, secreted phosphoprotein 1 was expressed at significantly higher levels in OSCC ([@b80-ol-0-0-10616]). According to a previous study, secreted protein acidic and cysteine rich had significant prognostic value, especially in the stroma surrounding OSCC ([@b81-ol-0-0-10616]). A literature search revealed that the interaction between HNC and the hub genes procollagen-lysine 2-oxoglutarate 5-dioxygenase (PLOD)-2, collagen type XII alpha 1 chain, multimerin 1 (MMRN1), plasminogen activator urokinase receptor, collagen type X α 1 chain, collagen type VI α 3 chain, prostaglandin-endoperoxide synthase 2, PLOD1, and complement factor D (CFD) has not been widely reported.

There were several limitations associated with the present study. First, only one series (GSE58911) downloaded and used from the GEO database. The number of tumor and normal samples in this series were both 15. This sample size was insufficient. Second, genes were analyzed that may be related to the carcinogenesis or progression of head and neck tumors from the results of the bioinformatics analyses. The functions of these genes have not been verified *in vitro* and *in vivo*. In the present study, the expression levels of IL8 (C-X-C motif chemokine ligand 8), IL1B and SERPINA1 in tumor tissues and normal tissues of patients with head and neck tumors were not verified further. In addition, phenotypic function was also not verified in head and neck tumor cell lines. In future studies this will be investigated. Third, the number of hub genes (modes with bold black circles) in [Fig. 2A](#f2-ol-0-0-10616){ref-type="fig"} is 21, and there are 5 hub genes (MMRN1, ECM1, TIMP metallopeptidase inhibitor 1, SERPINA1 and CFD) that do not appear in the network map. In particular, SERPINA1 is among one of the identified three genes following further analysis of the data. This could be due to the following reasons: i) These 5 genes may not be closely related to other genes, and have other roles and mechanisms in the occurrence and development of tumors, so they were excluded from the network map; ii) the 26 hub genes were obtained by analyzing 648 DEGs using the Cytoscape plug-in, MCODE. cBioPortal for Cancer Genomics was subsequently used to analyze these 26 hub genes to obtain a network map of hub genes and their co-expressed genes. The computer algorithms that each database performed for analysis may differ, and may also cause differences; iii) in addition, 3 hub genes (IL8, IL1B and SERPINA1) were selected for more in-depth analysis as cBioPortal for Cancer Genomics was used to analyze overall survival and disease-free survival rate for the 26 hub genes. Changes in the expression of IL8, IL1B and SERPINA1 in patients with head and neck tumors were associated with overall survival and disease-free survival rate, and were statistically significant; iv), a holistic analysis of 26 hub genes from 628 DEGs was performed in an attempt to obtain an inductive result ([Fig. 2](#f2-ol-0-0-10616){ref-type="fig"}). In addition, 2 detection methods (FISH and P16 tests) of HPV infection were used to obtain more accurate results for further analysis. However, the profiles of IL8, IL1B and SERPINA1 in [Fig. 2C and D](#f2-ol-0-0-10616){ref-type="fig"} are not consistent. This may be due to different detection methods or detection of HPV subtypes. This may require a more accurate method to detect the infection status of HPV for a more accurate analysis; and v), there are differences in the monitoring of overall survival and disease-free survival of patients between the gene alterations of IL8, IL1B and SERPINA1 ([Fig. 3](#f3-ol-0-0-10616){ref-type="fig"}). Monitoring was performed for over 180 months (over 15 years) when there were no alteration(s) in these 3 genes while alterations in these genes was monitored for only 20 months. This may be due to the following reasons: i) These samples were obtained at different time points over a 10-year period and as such the samples may have degraded; ii) some patients cannot be contacted during follow-up or have died due to illness. An open source, free database was used therefore information pertaining to when the samples were collected and whether it was in different decades. In this regard, the lack of data beyond 20 months may be considered a limitation associated with the present study. However, using this database for analysis is reliable and credible. This database is used in many articles on bioinformatics analysis ([@b82-ol-0-0-10616]--[@b84-ol-0-0-10616]). These limitations will be addressed in future studies. Despite these limitations, research in the present study is important as it elucidated molecular mechanisms underlying development of HNC, and also provides potential target genes for clinical diagnosis and targeted therapy. In addition, this provides direction for future studies of HNC.

In conclusion, the present study identified DEGs that may be involved in the carcinogenesis or progression of HNC. A total of 648 DEGs and 26 hub genes were identified and may have potential as target biomarkers for HNC. Further studies are needed to elucidate the biological functions of these genes in HNC.

Not applicable.

Funding
=======

This study was supported by the National Natural Science Foundation of China (grant nos. 81372880 and 81670910) and the Guidance fund of the Renmin Hospital of Wuhan University (grant no. RMYD2018Z12).

Availability of data and materials
==================================

All data are fully available without restriction.

Authors\' contributions
=======================

FC and ZT conceived and designed the study. FC, AZ, FL, SW, SC and ZT processed the data. FC wrote the paper. FC, AZ, FL, SW, SC, and ZT reviewed and edited the manuscript. All authors read and approved the manuscript.

Ethics approval and consent participate
=======================================

Not applicable.

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![Volcano plot and PPI network of DEGs. (A) DEGs were selected with a fold change ≥2 or ≤-2 and adjusted P-value \<0.05 in the GSE58911 dataset. The green dot indicates that the expression of the gene in the tumor was ≤one-half of that in the normal tissues, whereas the red dot indicates that the expression of the gene in the tumor was ≥ twice that of the normal tissues (P\<0.05). The black dots represent genes which were not considered differentially expressed. (B) The PPI network of DEGs was constructed using Cytoscape. PPI, protein-protein interaction. DEGs, differentially expressed genes; FC, fold-change.](ol-18-03-2955-g00){#f1-ol-0-0-10616}

![Analysis of hub genes and their co-expressed genes, and hierarchical clustering of hub genes. (A) Hub genes and their co-expressed genes were analyzed using cBioPortal. Nodes with bold black outlines represent hub genes. Nodes with thin black outlines represent co-expressed genes. The color in the circle represents the total alteration of the gene in the genomic profiles, including the up and downregulation. The intensity of the color depicts a larger alteration. The blue arrow represents a 'controls-state-change-of' interaction; whereas the green arrow represents a 'controls-expression-of' interaction. (B, C and D) Hierarchical clustering of hub genes was constructed using University of California Santa Cruz. (B) The samples grouped by the brown bar are non-cancerous samples and the samples grouped by the blue bar are HNC samples. The samples grouped by the brown bar are HPV-positive samples and the samples grouped by the blue bar are HPV-negative samples that were tested using. (C) Fluorescent *in situ* hybridization and (D) P16. Red indicates the upregulation of genes and blue indicates the downregulation of genes.](ol-18-03-2955-g01){#f2-ol-0-0-10616}

![(A) Overall survival and (B) disease-free survival analyses based on the expression of IL8, IL1B, and SERPINA1 were performed using the cBioPortal online platform. P\<0.05 was considered statistically significant. IL, interleukin; SERPINA1, serpin family A member 1.](ol-18-03-2955-g02){#f3-ol-0-0-10616}

![Oncomine analysis of cancer vs. normal tissue for IL8, IL1B and SERPINA1. Heat maps of IL8, IL1B, and SERPINA1 gene expression in clinical HNC samples vs. normal tissues. Red represents high expression and blue represents low expression and the color reflects the median rank, not the expression value. (A) 1. Head and neck squamous cell carcinoma vs. normal tissue ([@b21-ol-0-0-10616]). 2. Tongue squamous cell carcinoma vs. normal tissue ([@b22-ol-0-0-10616]). 3. Head and neck squamous cell carcinoma vs. normal tissue ([@b23-ol-0-0-10616]). 4. Thyroid gland papillary carcinoma vs. normal tissue ([@b24-ol-0-0-10616]). 5. Oral cavity squamous cell carcinoma vs. normal tissue ([@b25-ol-0-0-10616]). 6. Floor of the mouth carcinoma vs. normal tissue ([@b26-ol-0-0-10616]). 7. Oral cavity carcinoma vs. normal tissue ([@b26-ol-0-0-10616]). 8. Oropharyngeal carcinoma vs. normal tissue ([@b26-ol-0-0-10616]). 9. Tongue carcinoma vs. normal tissue ([@b26-ol-0-0-10616]). 10. Tonsillar carcinoma vs. normal tissue ([@b26-ol-0-0-10616]). 11. Tongue squamous cell carcinoma vs. normal tissue ([@b27-ol-0-0-10616]). (B) 1. Head and neck squamous cell carcinoma vs. normal tissue ([@b21-ol-0-0-10616]). 2. Tongue squamous cell carcinoma vs. normal tissue ([@b22-ol-0-0-10616]). 3. Head and neck squamous cell carcinoma vs. normal tissue ([@b23-ol-0-0-10616]). 4. Oral cavity squamous cell carcinoma vs. normal tissue ([@b23-ol-0-0-10616]). 5. Tongue squamous cell carcinoma vs. normal tissue ([@b27-ol-0-0-10616]). (C) 1. Head and neck squamous cell carcinoma vs. normal tissue ([@b23-ol-0-0-10616]). 2. Tall cell variant thyroid gland papillary carcinoma vs. normal tissue ([@b28-ol-0-0-10616]). 3. Thyroid gland papillary carcinoma vs. normal tissue ([@b28-ol-0-0-10616]). 4. Thyroid gland papillary carcinoma vs. normal tissue ([@b24-ol-0-0-10616]). 5. Oral cavity squamous cell carcinoma vs. normal tissue ([@b25-ol-0-0-10616]). 6. Oropharyngeal carcinoma vs. normal tissue ([@b26-ol-0-0-10616]). 7. Thyroid gland papillary carcinoma vs. normal tissue ([@b29-ol-0-0-10616]). IL, interleukin; SERPINA1, serpin family A member 1.](ol-18-03-2955-g03){#f4-ol-0-0-10616}

![Association between the expression of IL8, IL1B, and SERPINA1, tumor grade, and HPV infection status in the different datasets. The datasets were obtained from the Oncomine database. The box plot represents the maximum, the 75th percentile, the median, the 25^th^ percentile and the minimum value of data. (A-C) IL8, IL1B and SERPINA1 mRNA expression of HNC samples in the Cromer Head and Neck dataset. There were four patients in group 0, representing with no grade; seven patients in group 1, representing Grade 1; nineteen patients in group 2, representing Grade 2; and eight patients in group 3, representing Grade 3. (D-F) IL8, IL1B, and SERPINA1 mRNA expression of HNC samples in the Slebos Head and Neck dataset. There were twenty-eight patients in group 1, representing HPV negative; and eight patients in group 2, representing HPV positive. IL, interleukin; SERPINA1, serpin family A member 1; HPV, human papillomavirus, HNC, head and neck cancer.](ol-18-03-2955-g04){#f5-ol-0-0-10616}

###### 

GO and KEGG pathway enrichment analysis of DEGs in head and neck cancer.

  ID           Description                            Count in gene set   P-value
  ------------ -------------------------------------- ------------------- --------------
  GO:0003012   Muscle system process                  54                  1.63×10^−19^
  GO:0030198   Extracellular matrix organization      49                  1.86×10^−19^
  GO:0043062   Extracellular structure organization   49                  2.12×10^−19^
  GO:0006936   Muscle contraction                     48                  7.41×10^−19^
  GO:0030049   Muscle filament sliding                19                  7.21×10^−18^
  GO:0003779   Actin binding                          42                  1.61×10^−11^
  GO:0008307   Structural constituent of muscle       15                  1.63×10^−11^
  GO:0008092   Cytoskeletal protein binding           63                  2.75×10^−10^
  GO:0005198   Structural molecule activity           58                  1.91×10^−09^
  GO:0042805   Actinin binding                        9                   2.04×10^−06^
  GO:0044421   Extracellular region part              233                 1.75×10^−23^
  GO:0005576   Extracellular region                   258                 4.88×10^−22^
  GO:0043292   Contractile fiber                      45                  9.81×10^−22^
  GO:0030017   Sarcomere                              41                  3.45×10^−21^
  GO:0030016   Myofibril                              43                  6.08×10^−21^
  hsa04512     ECM-receptor interaction               18                  8.56×10^−10^
  hsa05146     Amoebiasis                             17                  1.28×10^−07^
  hsa04510     Focal adhesion                         22                  1.30×10^−06^
  hsa00982     Drug metabolism-cytochrome P450        12                  6.32×10^−06^
  hsa05204     Chemical carcinogenesis                12                  3.11×10^−05^
  hsa05414     Dilated cardiomyopathy                 12                  4.95×10^−05^
  hsa05222     Small cell lung cancer                 12                  5.54×10^−05^
  hsa05410     Hypertrophic cardiomyopathy            11                  1.31×10^−04^
  hsa00830     Retinol metabolism                     9                   8.20×10^−04^

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes.

###### 

GO and KEGG pathway enrichment analysis of DEGs in the hub genes.

  ID           Description                                Count in gene set   FDR
  ------------ ------------------------------------------ ------------------- --------------
  GO:0030198   Extracellular matrix organization          14                  1.89×10^−13^
  GO:0043062   Extracellular structure organization       14                  1.89×10^−13^
  GO:0030574   Collagen catabolic process                 9                   4.00×10^−11^
  GO:0044243   Multicellular organism catabolic process   9                   9.48×10^−11^
  GO:0032963   Collagen metabolic process                 9                   3.14×10^−09^
  GO:0004252   Serine-type endopeptidase activity         6                   0.041480238
  GO:0031012   Extracellular matrix                       16                  2.44×10^−13^
  GO:0005578   Proteinaceous extracellular matrix         14                  2.30×10^−12^
  GO:0005615   Extracellular space                        17                  3.11×10^−08^
  GO:0044421   Extracellular region part                  23                  3.86×10^−08^
  GO:0005576   Extracellular region                       24                  6.42×10^−08^
  hsa04610     Complement and coagulation cascades        5                   0.039461461

GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes; FDR, false discovery rate.

###### 

Abbreviations, official full names and synonyms for the 26 hub genes.

  Number   Gene symbol   Official full name                                  Also known as
  -------- ------------- --------------------------------------------------- ----------------------------------------------------------------
  1        TNC           Tenascin C                                          GP; JI; TN; HXB; GMEM; TN-C; DFNA56; 150--225
  2        PLOD2         Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2   LH2; TLH; BRKS2
  3        COL3A1        Collagen type III alpha 1 chain                     EDS4A; EDSVASC
  4        IL1B          Interleukin 1 beta                                  IL-1; IL1F2; IL1-BETA
  5        COL12A1       Collagen type XII alpha 1 chain                     UCMD2; BTHLM2; EDSMYP; COL12A1L; BA209D8.1; DJ234P15.1
  6        COL5A2        Collagen type V alpha 2 chain                       EDSC; EDSCL2
  7        MMRN1         Multimerin 1                                        ECM; MMRN; GPIa; EMILIN4
  8        IL8           C-X-C motif chemokine ligand 8                      NAF; GCP1; LECT; LUCT; NAP1; GCP-1; LYNAP; MDNCF; MONAP; NAP-1
  9        PLAU          Plasminogen activator, urokinase                    ATF; QPD; UPA; URK; u-PA; BDPLT5
  10       PLAUR         Plasminogen activator, urokinase receptor           CD87; UPAR; URKR; U-PAR
  11       ECM1          Extracellular matrix protein 1                      URBWD
  12       SERPINE1      Serpin family E member 1                            PAI; PAI1; PAI-1; PLANH1
  13       MMP9          Matrix metallopeptidase 9                           GELB; CLG4B; MMP-9; MANDP2
  14       TIMP1         TIMP metallopeptidase inhibitor 1                   EPA; EPO; HCI; CLGI; TIMP; TIMP-1
  15       COL10A1       Collagen type X alpha 1 chain                       
  16       CXCL12        C-X-C motif chemokine ligand 12                     IRH; PBSF; SDF1; TLSF; TPAR1; SCYB12
  17       COL6A3        Collagen type VI alpha 3 chain                      DYT27; UCMD1; BTHLM1
  18       MMP1          Matrix metallopeptidase 1                           CLG; CLGN
  19       PTGS2         Prostaglandin-endoperoxide synthase 2               COX2; COX-2; PHS-2; PGG/HS; PGHS-2; hCox-2; GRIPGHS
  20       PLOD1         Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1   LH; LH1; LLH; EDS6; PLOD; EDSKCL1
  21       MMP13         Matrix metallopeptidase 13                          CLG3; MDST; MANDP1; MMP-13
  22       SPP1          Secreted phosphoprotein 1pr                         OPN; BNSP; BSPI; ETA-1
  23       SERPINA1      Serpin family A member 1                            PI; A1A; AAT; PI1; A1AT; nNIF; PRO2275; alpha1AT
  24       CFD           Complement factor D                                 DF; ADN; PFD; ADIPSIN
  25       MMP3          Matrix metallopeptidase 3                           SL-1; STMY; STR1; CHDS6; MMP-3; STMY1
  26       SPARC         Secreted protein acidic and cysteine rich           OI17; BM-40
